)

MoonLake Immunotherapeutics (MLTX) investor relations material
MoonLake Immunotherapeutics R&D Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Pipeline overview and program updates
VELA-1 and VELA-2 phase 3 trials evaluated sonelokimab in adults with moderate to severe hidradenitis suppurativa (HS), enrolling over 800 patients with identical designs and endpoints, and over 90% completion at week 16.
Sonelokimab demonstrated a differentiated profile with strong efficacy, favorable safety, and convenient dosing.
All patients receive sonelokimab from week 16 onward in the VELA trials.
The program includes additional ongoing studies in PPP, PsA, axSpA, and adolescent HS, with key readouts expected from late 2025 through 2026.
Clinical trial data and development milestones
VELA-1 met all primary and secondary endpoints, while VELA-2's primary endpoint was not met under the composite strategy due to a high placebo response, but was significant under the treatment policy strategy.
HiSCR75 response rates at week 16 were 35% (VELA-1) and 36% (VELA-2) for sonelokimab, with a 17% delta to placebo and robust statistical significance.
Statistically significant improvements were observed in all key secondary endpoints, including HiSCR50, IHS4-55, pain reduction, HiSQOL, and DLQI, with benefits seen as early as week 4.
Sonelokimab's safety profile remained favorable, with no new safety signals and low rates of serious adverse events.
Efficacy continued to build beyond week 16, with strong cross-over responses and a week 52 readout planned.
R&D strategy and innovation priorities
Two pre-specified statistical strategies (composite and treatment policy) were used in accordance with regulatory advice to ensure robustness.
The development strategy leverages a robust pipeline in multiple inflammatory indications, with innovative trial designs and biomarker integration.
Nanobody® technology is highlighted for its potential advantages in tissue penetration, stability, and multivalent design.
Next MoonLake Immunotherapeutics earnings date

Next MoonLake Immunotherapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage